

FORM 1449*	
INROR	MATION DISCLOSURE STATEMENT
SEP 2 8 1998 2	IN AN APPLICATION
En S	(Use several sheets if necessary)
RADEMAN	

| Docket Number: | Application Number: | 11669.30US02 | 08/918,874

Applicant: Ashkenazi et al.

Filing Date: August 26, 1997 Group Art Unit: 1646

				U.S. PATENT DOCUMENT	s				
EXAMINER INITIAL	DOCUM	ENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	1		FO	REIGN PATENT DOCUME	NTS				
	DOCUM	ENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
				-			Œ	-	
•									
	ł	OT	HER DOCUMENT	S (Including Author, Title, Da	te Pertinent Pages	Etc.)		l	
07	T ₁		' <u>.</u>		,				
10-	2	Blast Results (A-1 - A55) Blast Results (B-1 - B23)							
· k	3	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF-kB and Protects against TRAIL-Mediated Apoptosis, yet Retains							
A		an Incomplet	e Death Domain," <u>I</u>	nmunity, 7:813-820 (1997).	NO and Trocec	is against TRAIL -Wee	uiateu Apoptosi	s, yet Ketaiiis	
4	4	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," J. Biol. Chem., 273:14363-14367 (1998).							
h	5	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <u>FEBS Letters</u> , 424:41-45 (1998).							
	6	Schneider et al., "Characterization of two receptors for TRAIL," FEBS Letters, 416:329-334 (1997).							
1	7	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <u>Current Biology</u> ,							

EXAMINER	John D	u	DATE CONSIDERED	17-3-0-58

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.